MedTrace Logo

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

NCT06636500 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-02-20

No results posted yet for this study

Summary

This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.

Conditions

  • Healthy Volunteer Study
  • Pain Management

Interventions

DRUG

CG001419

Oral doses

DRUG

Placebo

Oral doses

Sponsors & Collaborators

  • Cullgen Australia Pty Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-22
Primary Completion
2025-12-05
Completion
2025-12-05

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06636500 on ClinicalTrials.gov